Nautilus Biotechnology (NAUT)
Builds the Voyager platform for intact-protein and proteoform analysis.
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Kentaro Suzuki - Chief Marketing Officer Anna Mowry - CFO & Treasurer Conference Call Participants Ji-Yon Yi William Ruby - TD Cowen, Research Division Presentation Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Third Quarter 2025 Earnings Conference Call.
Nautilus Biotechnology, Inc. (NAUT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hello. Hi. My name is Yuko Oku, and I work on the Life Science Tools and Diagnostics team at Morgan Stanley.
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2025 Earnings Call July 31, 2025 8:30 AM ET Company Participants Anna Mowry - CFO & Treasurer Parag Mallick - Co-Founder, Chief Scientist & Director Sujal M. Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Daniel Gregory Brennan - TD Cowen, Research Division Subhalaxmi T.
26,324 Shares in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC acquired a new position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,324 shares of the company’s stock, valued at approximately $44,000. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Nautilus Biotechnology during the fourth quarter worth about $28,000. Cubist Systematic Strategies LLC bought a new position in Nautilus Biotechnology during the fourth quarter worth about $34,000. SG Americas Securities LLC boosted its position in Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC boosted its position in shares of Nautilus Biotechnology by 45.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock valued at $48,000 after acquiring an additional 8,888 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $63,000. Institutional investors own 50.71% of the company’s stock. Nautilus Biotechnology Stock Down 2.7% Shares of NASDAQ NAUT opened at $0.75 on Wednesday. Nautilus Biotechnology, Inc. has a 52 week low of $0.66 and a 52 week high of $3.09. The company has a market cap of $94.74 million, a price-to-earnings ratio of -1.34 and a beta of 1.43. The firm’s fifty day moving average is $0.75 and its 200 day moving average is $1.32. Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Equities research analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year. Insider Activity at Nautilus Biotechnology In other Nautilus Biotechnology news, CEO Sujal M. Patel purchased 53,300 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the purchase, the chief executive officer now directly owns 10,117,788 shares of the company’s stock, valued at $10,016,610.12. This trade represents a 0.53% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders purchased 81,800 shares of company stock worth $74,172. 41.10% of the stock is owned by company insiders. Wall Street Analyst Weigh In Separately, Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a research report on Friday, February 28th. Get Our Latest Stock Analysis on NAUT Nautilus Biotechnology Company Profile (Free Report) Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. Read More Five stocks we like better than Nautilus Biotechnology What is the Euro STOXX 50 Index? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What Does Downgrade Mean in Investing? Casey’s Surges on Strong Q4, More Gains Likely Ahead What does consumer price index measure? Government Mandate Sends eVTOL Stocks Flying
Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Elizabeth Kolsky - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilus First Quarter 2025 earnings conference call.
Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Will Ortmayer - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilus Fourth Quarter and Full Year 2024 Earnings Conference Call.
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executive Officer Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Operator Good day everyone, and thank you for standing by and welcome to Nautilus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tycho Peterson - Jefferies Dan Brennan - TD Cowen Operator Good day and thank you for standing by and welcome to Nautilus Q2 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know
Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Q1 2024 Earnings Conference Call.
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference.
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.